Martin Bögemann

German Multicenter Study Investigating¹⁷⁷Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients

Kambiz Rahbar, Hojjat Ahmadzadehfar, Clemens Kratochwil et al. · Journal of Nuclear Medicine · 2016 · 812 citations · Full text

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Thomas Powles, Michiel S. van der Heijden, Daniel Castellano et al. · The Lancet Oncology · 2020 · 485 citations · Full text

Surgical Oncology, Urology, Metastatic Urothelial Carcinoma +8

Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study

Hojjat Ahmadzadehfar, Kambiz Rahbar, Stefan Kürpig et al. · EJNMMI Research · 2015 · 289 citations · Full text

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1

Matthew R. Smith, Johann S. de Bono, Cora N. Sternberg et al. · Journal of Clinical Oncology · 2016 · 244 citations

Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial

Maha Hussain, Bertrand Tombal, Fred Saad et al. · Journal of Clinical Oncology · 2023 · 196 citations · Full text